NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02023710,Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma,https://clinicaltrials.gov/study/NCT02023710,,UNKNOWN,Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated metastatic mucosal melanoma to characterize the efficacy and safety of bevacizumab when combined with carboplatin plus paclitaxel.,NO,Melanoma,DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Bevacizumab,"progress-free survival(PFS), Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause., From randomization up to 144 weeks","adverse event(AE), Any events,no matter related to interventions,occur during the period from the enrollment to death or 30 days after withdrawal from the trial, From randomization up to144 weeks|Overall Survival(OS), Overall survival was defined as the time from randomization to death from any cause., Up to 144 weeks",,Peking University Cancer Hospital & Institute,,ALL,"ADULT, OLDER_ADULT",PHASE2,182,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BCH-MM-131101,2013-12,2017-12,2017-12,2013-12-30,,2017-05-09,"Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, China|Beijing Cancer Hospital, Beijing, 100142, China|Yunan Tumor Hospital, Kunming, 650106, China",
